Novo Nordisk says it expects to launch its long-acting haemophilia B drug Refixia in the European Union in the fourth quarter of this year after receiving a green light from regulators.
Six new medicines, including three orphan drugs for rare diseases, have been backed for European Union approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).